A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure

A Study to Describe Vascular and Renal Effects and Safety of Valsartan 80 and 160 mg in Arterial Hypertension Patients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00171353

Enrollment

109

Registered

2005-09-15

Start date

2004-07-31

Completion date

2005-09-30

Last updated

2011-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

arterial hypertension, albuminuria, valsartan

Brief summary

One hundred twenty patients with arterial hypertension and albuminuria (some amount of albumin in urine) are given valsartan 80 mg and then160 mg to normalize blood pressure. Hydrochlorothiazide (diuretic) 12.5-25 mg added if necessary.

Interventions

DRUGvalsartan

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to 65 Years

Inclusion criteria

* Arterial hypertension without previous regular treatment * Urinary albumin excretion rate above 30 mg / 24h * 30-65 years old

Exclusion criteria

* Reno-vascular arterial hypertension * Therapy resistant edema * Chronic heart failure, angina pectoris * Diabetes mellitus Other protocol-defined

Design outcomes

Primary

Measure	Time frame
Change from baseline in urine albumin excretion after 24 weeks	—
Change from baseline in an ultrasound measurement of blood flow after 24 weeks	—

Secondary

Measure	Time frame
Effect of blood pressure changes on urine albumin excretion rate and blood vessel function	—

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026